SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ALXO

Alx Oncology Holdings Inc (ALXO)

NASDAQ: ALXO · USD
Healthcare · Biotechnology
$1.06+$0.04 (+3.92%)
 
Market cap
$137M
Insider Score
Analyst consensus
Market Cap$137.03M-22.1%
Revenue (ttm)n/a
Net Income-$80.57M
EPS-$0.87
Shares Out129.27M
PE Ration/a
Forward PE-1.97
Dividendn/a
Ex-Dividend Daten/a
Volume997,708
Open$1.01
Previous Close$1.02
Day's Range$0.98 - $1.11
52-Week Range$0.86 - $2.66
Beta0.56
AnalystsStrong Buy
Price Target$4.60(+333.96%)
Earnings DateNov 16, 2026

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Address
323 Allerton Avenue, South San Francisco, CA, 94080, United States
Market Cap
137 million
Employees
49
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$42.59K
Bought
$5.00M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
+3.92%
5 Days
+1.92%
1 Month
-10.92%
6 Months
-46.46%
1 Year
-22.06%

$ALXO stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ALXO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ALXO's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ALXO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ALXO Revenue by Segment

$16.18MTotal
Clinical and development costs$11.17M69.06%
Personnel and related costs$3.68M22.76%
Other research costs$916.00K5.66%
Preclinical costs$409.00K2.53%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ALXO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ALXO from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ALXO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Bullish analyst commentary on clinical data and Q3 earnings report with corporate guidance; concrete business developments outweigh typical investor conference appearances.

Recent Insider Activity

Buys
1
Sells
7
Buy Value
$5.00M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.21%
QQQSInvesco NASDAQ Future Gen 200 ETF0.33%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.16%
FSEGFidelity Enhanced Small Cap Growth ETF0.01%

Weight is the stock’s share of each fund’s holdings.